897732-93-3

Basic information

• Product Name: JNJ-38431055
• Synonyms: APD597;JNJ-38431055;APD597 (JNJ-38431055);4-[[6-[(6-Methylsulfonyl-2-methylpyridin-3-yl)amino]-5-methoxypyrimidin-4-yl]oxy]piperidine-1-carboxylic acid isopropyl ester
• CAS NO: 897732-93-3
• Molecular Formula: C21H29N5O6S
• Molecular Weight: 479.54986
• Mol File: 897732-93-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 648.3±55.0 °C(Predicted)
• Appearance: /
• Density: 1.311±0.06 g/cm3(Predicted)
• PKA: 2.43±0.10(Predicted)
• CAS DataBase Reference: JNJ-38431055(CAS DataBase Reference)
• NIST Chemistry Reference: JNJ-38431055(897732-93-3)
• EPA Substance Registry System: JNJ-38431055(897732-93-3)

Safety Data

• Hazardous Substances Data: 897732-93-3(Hazardous Substances Data)

Usage

General Description

JNJ-38431055 is a potent and selective dopamine D4 receptor partial agonist that has shown potential for the treatment of cognitive deficits associated with schizophrenia and other neuropsychiatric disorders. It has been found to improve cognitive function and working memory in preclinical studies, with the potential to enhance cognitive performance without the typical side effects seen with other antipsychotic medications. The compound has also demonstrated antipsychotic-like effects in animal models, further supporting its potential as a novel treatment for schizophrenia and related disorders. Overall, JNJ-38431055 represents a promising candidate for the development of new therapies targeting cognitive dysfunction in neuropsychiatric disorders.

Upstream product

• 832715-51-2 isopropyl 4-hydroxypiperidine-1-carboxylate 
• 1224097-06-6 (6-chloro-5-methoxy-pyrimidin-4-yl)-(6-methanesulfonyl-2-methyl-pyridin-3-yl)-amine 
• 897732-75-1 2-methyl-6-(methylsulfonyl)pyridin-3-amine 
• 897732-25-1 4-(6-chloro-5-methoxy-pyrimidin-4-yloxy)-piperidine-1-carboxylic acid isopropyl ester 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF TRI-SUBSTITUTED PYRIDINE AND TRI-SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL AS GDIR AGONISTS

The present invention is directed to novel processes for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives, useful as glucose dependent insulinotropic receptor agonist, for the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.

CRYSTALLINE FORMS OF 4-[6-(6-METHANESULFONYL-2-METHYLPYRIDIN-3-YLAMINO)-5-METHOXY-PYRIMIDIN-4-YLOXY]-PIPERIDINE-1-CARBOXYLIC ACID ISOPROPYL ESTER

The present invention is directed to a novel crystalline forms of 4-[6-(6- methanesulfonyl-2-methyl-pyhdin-3-ylamino)-5-methoxy-pyhmidin-4-yloxy]- piperidine-1 -carboxylic acid isopropyl ester, pharmaceutical compositions containing said crystalline form and the use of said crystalline forms in the treatment of metabolic related disorders. The present invention is further directed to processes for the preparation of the crystalline forms of 4-[6-(6- methanesulfonyl-2-methyl-pyhdin-3-ylamino)-5-methoxy-pyhmidin-4-yloxy]- piperidine-1 -carboxylic acid isopropyl ester.

Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto

The present invention relates to certain substituted pyridinyl and pyrimidinyl derivatives of Fomula (Ia) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and com